(UroToday.com) In a plenary presentation in the Progress and Promise in Treatment Personalization for Advanced Prostate Cancer session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Dr. Sathekge provided a talk examining the role of Lutetium in prostate cancer.
(UroToday.com) There has been rapid evolution in treatment options for patients with non-metastatic castration-resistant prostate cancer since the spring of 2018. Up until the presentation of SPARTAN and PROSPER trials, reporting on the use of apalutamide and enzalutamide in non-metastatic castration-resistant prostate cancer, at GU ASCO in February 2018, there were no specifically approved treatment […]
(UroToday.com) Standard of care for high-risk non-muscle-invasive bladder cancer (NMIBC) is transurethral resection of the bladder tumor followed by intravesical Bacillus Calmette-Guérin (BCG) immunotherapy, although many patients will become BCG-unresponsive and experience recurrence within 12 months. Pembrolizumab was approved in January 2020 for treatment of patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ […]
(UroToday.com) Muscle-invasive bladder cancer is a systemic disease as >40% of patients ultimately develop recurrence after radical cystectomy. For patients who cannot receive or refuse cisplatin-based chemotherapy, there is no standard-of-care neoadjuvant therapy. Single-agent pembrolizumab, given in the neoadjuvant setting in patients with T2-4N0M0 muscle-invasive bladder cancer, documented a 42% pathologic complete response-rate (ypT0N0) in the […]
(UroToday.com) Genomics, both of the tumor (somatic) and germline, are increasingly being incorporated into clinical oncologic care, both with regard to specific targeted therapy selections (e.g. PARP inhibitors) and therapy intensity (e.g. aggressive variants, e.g. genomic alterations inRB1, TP53). Often re-biopsy can impose an additional barrier for a patient, or is limited by site of metastasis, such as bone. These realities are […]
(UroToday.com) Rucaparib is an inhibitor of poly (ADP-ribose) polymerase – PARP – that is approved for the treatment of BRCA1 and BRCA2 mutated metastatic castration-resistant prostate cancer (mCRPC) based on the recently published TRITON2 study. Enzalutamide is an androgen receptor antagonist that is approved for the treatment of mCRPC as well as metastatic castration sensitive prostate […]
(UroToday.com) The POUT trial (CRUK/11/027; NCT01993979) previously reported that adjuvant chemotherapy improves disease free survival (HR 0.45, 95% CI 0.30-0.68) for patients with histologically confirmed pT2-T4 N0-3 M0 upper tract urothelial carcinoma over a median follow-up of 30.3 months.1 At the GU ASCO 2021 annual meeting Dr. Alison Birtle and colleagues presented results of a pre-planned […]
(UroToday.com) Shared decision-making regarding cancer treatment is critical. In previous PRIME educational programs involving patients with bladder cancer and their care teams, effective shared decision-making was found to be integral to the development of treatment plans that reflected patient preferences and treatment goals. However, oncology care teams face complex barriers that impede their ability to personalize […]
(UroToday.com) Cabozantinib, nivolumab, and ipilimumab have been increasingly utilized for a number of genitourinary malignancies, most prominently in renal cell carcinoma. In a dose-escalation study, combinations of cabozantinib and nivolumab (CaboNivo) and cabozantinib, nivolumab, and ipilimumab (CaboNivoIpi) demonstrated promising efficacy and safety in a dose-escalation phase I study. In a plenary abstract presentation in the Rapid Abstract […]
(UroToday.com) Prostate cancer screening using prostate-specific antigen (PSA) testing has been controversial since shortly after its introduction in large part due to concerns of over-diagnosis and over-treatment, with the associated morbidity. Thus, despite improvements in prostate cancer-related metastasis and mortality demonstrated in the European Randomized Study of Screening for Prostate Cancer (ERSPC) randomized trial from Europe, […]
